A proton magnetic resonance spectroscopic study in ALS: Correlation with clinical findings

Neurology

Volumn 51, Issue 4, 1998, Pages 1104-1109

  Ellis, C M ^a   Simmons, A ^a,b   Andrews, C ^b   Dawson, J M ^a,b   Williams, S C R ^a,b   Leigh, P N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

EID: 0031666673     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.4.1104     Document Type: Article

References (14)

1. Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR. Proton spectroscopy in vivo. Magn Reson Q 1993;9(1):31-59.
2. Williams SCR. In vivo proton spectroscopy. In: NMR basic principles and progress. Vol 28. Berlin: Springer-Verlag, 1992: 55-70.
3. Ploro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magn netic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933-1938.
4. Jones AP, Gunawardena WJ, Coutinho CMA, Gatt JA, Shaw IC, Mitchell JD. Preliminary results of proton magnetic resonance spectroscopy in motor neuron disease (amyotrophic lateral sclerosis). J Neurol Sci 1995;129(suppl):85-89.
5. Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localised proton magnetic resonance spectroscopy. Neurology 1997;48:878-881.
6. World Federation of Neurology Research Group on Neuromuscular Disorders. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107.
7. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikao N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 1989;8:142-150.
8. Sobel DF, Gallen CC, Schwartz BJ, et al. Locating the central sulcus: comparison of MR anatomic and magnetoencephalographic functional methods. AJNR Am J Neuroradiol 1993;14: 915-925.
9. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 1994;241:354-371.
10. Simmons A, Smail M, Moore E, Williams SCR. Serial precision of metabolite peak area ratios and water referenced metabolite concentrations in proton MR spectroscopy of the human brain. Magn Reson Imaging 1998;16:319-330.
11. Tsai GC, Stauch-Slusher B, Sim L, et al. Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res 1991;556:151-156.
12. Huppl PS. Regional metabolic assessment of human brain during development by proton magnetic resonance spectroscopy in vivo and by high performance liquid chromatography/ gas chromatography in autopsy tissue. Pediatr Res 1995; 37(2):145-150.
13. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet 1991; 337:58-59.
14. Ellis CM, Lemmens G, Williams SCR, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997;49:438-444.